These findings confirmed that normal tenocyte viability remained largely unaffected in the combination treatment groups compared to doxo alone, suggesting that HDAC inhibitors selectively target osteosarcoma cells while sparing normal cells. The gene discussed is HDAC9; the disease is osteosarcoma.